Instrument Inactif

Communiqués Biosyent Inc. Toronto S.E.

Actions

RX

CA0906901081

Produits pharmaceutiques

Communiqués

25/09	BioSyent Named as One of Canada’s Top Growing Companies 2026 by The Globe and Mail	GL
20/08	BioSyent Releases Financial Results for Q2 and H1 2026	GL
20/08	BioSyent Declares Third Quarter 2026 Dividend	GL
13/08	BioSyent Schedules Q2 and H1 2026 Earnings Release for August 20, 2026	GL
15/06	BioSyent to Present at Planet MicroCap Las Vegas	GL
19/05	BioSyent annonce l’approbation de Thyconvi(MD) par Santé Canada (solution orale de lévothyroxine)	GL
19/05	BioSyent Announces Health Canada Approval of Thyconvi™ (levothyroxine oral solution)	GL
15/05	BioSyent : Financial Statements Q1 2026	PU
15/05	BioSyent : MDA Q1 2026	PU
15/05	BioSyent : Results Presentation Slides Q1 2026	PU
15/05	BioSyent Declares Second Quarter 2026 Dividend	GL
15/05	BioSyent Releases Financial Results for First Quarter 2026	GL
08/05	BioSyent Schedules First Quarter 2026 Earnings Release for May 14, 2026	GL
15/04	BioSyent to Present at 2026 Bloom Burton & Co. Healthcare Investor Conference	GL
01/04	FeraMAX is Canada's Top-Ranked Iron Supplement for 11 Consecutive Years	GL
01/04	FeraMAX est le supplemént de fer le plus recommandé au Canada depuis 11 années consécutives	GL
24/03	BioSyent Announces Grant of Restricted Share Units	GL
19/03	BioSyent Releases Financial Results for Fourth Quarter and Full Year 2025	GL
19/03	BioSyent : MDA 2025 Q4	PU
19/03	BioSyent : Results Presentation Slides Q4 2025	PU
12/03	BioSyent Schedules Fourth Quarter and Full Year 2025 Earnings Release for March 19, 2026	GL
02/03	BioSyent Announces Closing of the Acquisition of Oral Science Inc.	GL
09/02	BioSyent to Acquire Oral Science Inc.	GL
29/01	BioSyent Declares First Quarter 2026 Dividend	GL
15/12	BioSyent Announces Renewal of Normal Course Issuer Bid	GL